SCHEMBL16611010

SCHEMBL16611010

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2C1CCCCC1(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.38
GSK3B P49841 1/20 0.38
FYN P06241 1/20 0.36
ALOX5 P09917 4/20 0.35
PRKDC P78527 2/20 0.34
CFTR P13569 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MERTK Q12866 3/20 0.33
CASP1 P29466 2/20 0.33
CASP7 P55210 2/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611339 0.82 LRRK2 (0.39) LRRK2GSK3BFYNALOX5PRKDC
SCHEMBL16610876 0.81 SLC18A3 (0.41) LRRK2GSK3BFYNALOX5PRKDC
SCHEMBL16611420 0.78 ZAP70 (0.37) CFTR
SCHEMBL16610837 0.77 LRRK2 (0.44) LRRK2GSK3BFYNPRKDCCFTR
SCHEMBL16610962 0.73 MAP4K1 (0.41) LRRK2GSK3BFYNPRKDCKDM4E
SCHEMBL16610911 0.71 TSHR (0.41) LRRK2GSK3BFYNKDM4EMEN1
SCHEMBL16611322 0.69 TBK1 (0.43) LRRK2GSK3BPRKDCKCNH2CDK1
SCHEMBL16611763 0.68 CCNA2 (0.43) LRRK2GSK3BPRKDCALDH1A1MAPT
SCHEMBL16610949 0.67 LRRK2 (0.74) LRRK2
SCHEMBL16611225 0.66 TGFBR1 (0.42) LRRK2PRKDCL3MBTL1MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885GSK3B 3280/4885FYN 712/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885GSK3B 3280/4885FYN 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.